2024 World Conference on Lung Cancer (WCLC) - Posters-P2.10B.07 Chemotherapy in Combination with Anti-PD1 in PD-L1-Negative Non-Small Cell Lung Cancer Patients: A Single-Center Experience

P2.10B.07 Chemotherapy in Combination with Anti-PD1 in PD-L1-Negative Non-Small Cell Lung Cancer Patients: A Single-Center Experience

Back to course

Pdf Summary

This single-center study explores the effectiveness of combining chemotherapy with anti-PD-1 therapy in patients with PD-L1-negative non-small cell lung cancer (NSCLC). NSCLC is a prevalent and fatal cancer, with patients in advanced stages lacking effective treatment options, especially those without actionable mutations. The study retrospectively assessed 45 patients diagnosed with adenocarcinoma or squamous cell carcinoma, all PD-L1-negative, treated from 2019 onwards.<br /><br />Key findings include:<br /><br />- **Patient Demographics**: Patients had a median age of 68 years. Pulmonary metastases were noted at diagnosis in 51.1% of patients, with other metastases including bone (37.8%), lymph nodes (26.7%), brain (11.1%), and liver (6.7%).<br />- **Treatment Outcomes**: The median progression-free survival (PFS) was 7 months, and overall survival (OS) was 8 months. Progression often affected the lungs, and only a minority (20%) received second-line treatment post-progression.<br />- **Genetic Findings**: Next Generation Sequencing identified KRAS mutations in 17% of cases, associated with brain metastasis, while other mutations included MET and TP53.<br />- **Survival Challenges**: While the chemo-anti-PD1 combination shows promise in improving survival outcomes, the advanced age and higher tumor burden of the patient cohort pose significant therapeutic challenges compared to pivotal trials.<br /><br />The study concludes that the survival of NSCLC patients remains challenging, but with larger future patient cohorts, more tailored strategies can enhance outcomes. The study underlines the potential of combining chemotherapy with immunotherapy for improved management of NSCLC, although further research is necessary to refine treatment strategies for this group.

Asset Subtitle

Silvia SEQUERO LÓPEZ

Meta Tag

Speaker Silvia SEQUERO LÓPEZ

Topic Metastatic NSCLC – Cytotoxic Therapy

Keywords

NSCLC

chemotherapy

anti-PD-1 therapy

PD-L1-negative

adenocarcinoma

squamous cell carcinoma

progression-free survival

KRAS mutations

immunotherapy

treatment outcomes